2023
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Peer-Reviewed Original Research
2015
Predictors of warfarin‐associated adverse events in hospitalized patients: Opportunities to prevent patient harm
Metersky ML, Eldridge N, Wang Y, Jaser L, Bona R, Eckenrode S, Bakullari A, Andrawis M, Classen D, Krumholz HM. Predictors of warfarin‐associated adverse events in hospitalized patients: Opportunities to prevent patient harm. Journal Of Hospital Medicine 2015, 11: 276-282. PMID: 26662851, DOI: 10.1002/jhm.2528.Peer-Reviewed Original ResearchConceptsAdverse eventsWarfarin-related adverse eventsHospitalized patientsOdds ratioINR monitoringPneumonia patientsINR measurementsFrequent INR monitoringPredictors of warfarinRetrospective cohort studyAcute cardiac diseaseAcute care hospitalsFrequency of warfarinCohort studyCare hospitalSurgical patientsCardiac patientsCardiac diseasePatientsPatient harmWarfarinSignificant associationINRMore daysMonitoring System data